• Coralie Briand, Catherine Dollfus, Albert Faye, Elie Kantor, Véronique Avettand-Fenoel, Marion Caseris, Diane Descamps, Véronique Schneider, Marie-Dominique Tabone, Geneviève Vaudre, Florence Veber, Stéphane Blanche, and Pierre Frange.
• Unité d'Immunologie, Hématologie et Rhumatologie Pediatriques, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Universitaire Necker - Enfants Malades, Paris, France.
• J. Antimicrob. Chemother. 2017 Mar 1; 72 (3): 837-843.

ObjectivesTo assess the safety and efficacy of a dolutegravir-based regimen in perinatally HIV-1-infected adolescents.Patients And MethodsWe conducted a retrospective multicentre study of 50 adolescents beginning dolutegravir-based treatment regimens between January 2014 and December 2015. Clinical and biological data collected before and after dolutegravir initiation were analysed. The primary endpoint was the proportion of patients achieving a plasma viral load (PVL) <50 copies/mL within 3 months of dolutegravir initiation (for patients with detectable viraemia at baseline) and maintaining virological suppression (PVL <50 copies/mL) until the last follow-up visit (for all patients).ResultsVirological suppression was noted for 17/50 adolescents at baseline. Dolutegravir-based regimens maintained virological success in 14/17 patients (82%). The other three patients experienced a transient viral rebound, before PVL fell to < 50 copies/mL again, with no need to change the antiretroviral regimen. Thirty-three viraemic adolescents were enrolled. All but one had already received antiretroviral drugs. Virological success was achieved and maintained in 19/33 subjects (58%). Another three adolescents with initial virological failure had an undetectable PVL at the end of follow-up, with reinforced measures to improve compliance. Overall, sustained virological success was observed in 66% of patients and 78% of patients had an undetectable PVL at the last visit. Dolutegravir was well tolerated. Only one patient stopped treatment for severe drug-related adverse effects (dizziness and sleep disturbance). No emergence of resistance mutations was observed in patients with virological failure.ConclusionsDolutegravir was safe and virologically effective in these patients, for whom multiple interventions were required to improve compliance.© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

30 keywords...

hide…